Table 1.
Baseline characteristics of eligible patients
| Characteristic | AVETUX regimen |
| n=39 | |
| Sex, no. (%) | |
| Male | 26 (67) |
| Female | 13 (33) |
| Age | |
| Median years (range) | 62 (29–82) |
| ECOG performance status, n (%) | |
| 0 | 28 (72) |
| 1 | 11 (28) |
| Site of primary tumor, n (%) | |
| Left (splenic flexure-rectum) | 36 (92) |
| Right (transverse colon- caecum) | 3 (8) |
| Microsatellite status, n (%) | |
| MSI-H | 2 (5) |
| MSI-L | 1 (3) |
| MSS | 36 (92) |
| Prior adjuvant chemotherapy, n (%) | |
| Single agent fluoropyrimidine | 3 (8) |
| Oxaliplatin based | 9 (23) |
| Metastatic sites, n (%) | |
| Liver | 30 (77) |
| Lung | 12 (31) |
| Lymph node (distant) | 18 (46) |
| Bone | 3 (8) |
| Other soft tissue | 5 (13) |
| Ascites | 1 (3) |
| Pleural effusions | 1 (3) |
| Other | 7 (18) |
ECOG, Eastern Cooperative Oncology Group; MSI, microsatellite instability – high (H) or low (L); MSS, microsatellite stable.